
Colorectal cancer (CRC) is the second leading cause of cancer mortality in the United States, yet it remains the most preventable malignancy due to its slow, decade-long progression from benign polyps to malignancy. Unlike screening tools for breast or lung cancer, a colonoscopy provides the unique dual benefit of direct visualization and the immediate removal of precancerous lesions before they become cancerous. While current CDC estimates suggest that standard screening intervals could prevent 68% of the 55,000 annual CRC deaths, more aggressive protocols—including earlier start dates and more frequent intervals—could potentially eliminate mortality entirely. Addressing the troubling rise in early-onset cases among younger adults is critical, as is understanding the specific limitations of non-invasive alternatives like stool-based or blood-based tests compared to the gold-standard colonoscopy. Proper screening transforms a potentially fatal disease into a manageable and avoidable condition.
Sign in to continue reading, translating and more.
Continue